Jason Kelly (Ginkgo Bioworks)
Jason Kelly is an American biological engineer and co-founder and CEO of Ginkgo Bioworks. Raised in FloridaFloridaFlorida is a U.S. state occupying mainly the Florida peninsula, with its capital at Tallahassee; its most populous city is Jacksonville. It entered the Union on March 3, 1845, as the 27th state, and had a population of 21,538,187 in the 2020 census (April 1, 2020).Open the full entry, he studied chemical engineering and biology at MITMassachusetts Institute of TechnologyThe Massachusetts Institute of Technology (MIT) is a private research university in Cambridge, Massachusetts, United States. It received its charter from Massachusetts in 1861, admitted its first students in 1865 and moved from Boston to its present campus in 1916. As of October 2025 it had 11,816 students, and it counts 106 Nobel laureates among members of its community.Open the full entry and earned a doctorate in biological engineering there. He and four colleagues turned a research collaboration into a Boston company in 2008. He later chaired the US National Security Commission on Emerging Biotechnology.
Contents7 sections
Key facts
Early life in Florida and education at MIT
Kelly recalled growing up in Florida and arriving at MIT for undergraduate studies already wanting to become a genetic engineer. The available courses of study did not map neatly onto that ambition. He studied chemical engineering and biology and stayed at MIT for a doctorate in biological engineering. His future company partners included Tom Knight, Reshma Shetty, Barry Canton and Austin Che.[1][2][3]
From 2008Building a public company from a research collaboration
The five partners started Ginkgo Bioworks in 2008 with Kelly as CEO and a director. With venture funding difficult to secure during the financial crisis, early projects depended on grants. The company joined Y CombinatorY CombinatorY Combinator (YC) is a startup accelerator and seed investor founded in 2005 by Paul Graham, Jessica Livingston, Robert Morris and Trevor Blackwell. It supports startups through investments made in batches, three months of intensive guidance, Demo Day and an alumni network. Its early companies included Dropbox, Airbnb and Stripe.Open the full entry in 2014 and built research infrastructure in Boston for customers in pharmaceuticals, food, chemicals and agriculture. It became publicly traded in 2021. In a 2026 interview Kelly described the problems of financing long-term research, board governance and running a platform business.[1][3][2]
2022–2024Chairing a federal commission
On December 30, 2022, the leadership of the House and Senate Armed Services Committees announced Kelly's selection as chair of the National Security Commission on Emerging Biotechnology, with Michelle Rozo as vice chair. The commission submitted its interim report in December 2023. On September 12, 2024, it announced Senator Todd Young as its new chair. Kelly said he was returning his full attention to Ginkgo.[4][5]
September 28, 2023Interview with No Priors
Kelly appeared on No PriorsNo PriorsNo Priors is an AI interview podcast and media brand founded and hosted by investors Sarah Guo and Elad Gil, with episodes beginning in February 2023. It covers research, startups, infrastructure and business applications through guest interviews, host discussions and retrospectives distributed on audio platforms and YouTube.Open the full entry to discuss the role of AI in the life sciences, the relationship between instruments, software and research data, and maintaining the capacity for long-term public health monitoring and coordination.[6]
He described a Ginkgo business arrangement in which the customer licensed the work and took responsibility for developing a product, while Ginkgo received payments along the way and a royalty.[6]
Advice Shared on No Priors
He suggested testing a platform business by asking whether infrastructure built for one customer could serve the next. Rebuilding for every customer would limit the benefits of scale. (17:07)[6]
He suggested considering employees for long-term voting power because they lived with the consequences of the work and had to explain to others why they were proud to do it. (30:24)[6]
Related Organizations, Websites and Public Accounts
Ginkgo Bioworks: Co-founder, CEO and director. Official website: https://www.ginkgo.bio/ (opens in a new window).[3]
Sources6 sources
- From PhD to Public Company: Jason Kelly on Building Ginkgo and What Comes Next (opens in a new window)portal.bio↑
- Jason Kelly, Ph.D.: Co-Founder and CEO, Ginkgo Bioworks (opens in a new window)uscc.gov↑
- Governance: Ginkgo Bioworks leadership (opens in a new window)investors.ginkgobioworks.com↑
- Armed Services Committees Leadership Announces Chair and Vice Chair Selections for National Security Commission on Emerging Biotechnology (opens in a new window)armed-services.senate.gov↑
- National Security Commission on Emerging Biotechnology Selects Senator Todd Young as Chair (opens in a new window)biotech.senate.gov↑
- No Priors Ep. 34 | With Ginkgo Bioworks Co-Founder and CEO Jason Kelly (opens in a new window)youtube.com↑